In Brief: Respiratory Depression with Gabapentinoids

Date: June 1, 2020 Issue #:  1599Summary:  The FDA has required new warnings in the labels of gabapentin (Neurontin, and others) and pregabalin (Lyrica,Lyrica CR, and generics) about the risk of life-threatening or fatal respiratory depression in patients with respiratory risk factors. Respiratory risk factors include chronic obstructive pulmonary disease (COPD) and concurrent use of opioids or other CNS depressants. Elderly patients are also at increased risk.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: COPD Drug Safety Gabapentin Lyrica Neurontin Opioids Pregabalin Source Type: research